Novel bio-ink and application thereof in treatment of glottis insufficiency

Through novel bioink formulas, including GeIMA, AAM, PEGDA and Gelatin, the problem of insufficient absorption and mechanical properties of bioinks in glottal incomplete treatment in the prior art is solved, and high performance, injectability and biocompatibility are achieved. A porous hydrogel scaffold that meets stem cell loading and 3D printing tissue repair needs.

CN119015499APending Publication Date: 2024-11-26SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410644992.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing bioinks are easily absorbed when treating glottal incomplete closure, and have poor long-term efficacy and are difficult to form an efficient grade-level pore stent structure. In addition, traditional methods require repeated injections, which cannot meet the mechanical properties requirements of tissue repair.

Method used

A new bioink formula, including 3-5% GeIMA, 2-4% AAM, 1-5% PEGDA, 1-3% PEO and 7-9% Gelatin, was prepared by liquid phase stencil method, with excellent formation performance, Porous hydrogel scaffold with good compression resistance meets stem cell load and 3D printing needs.

Benefits of technology

It realizes high performance, good printability and biocompatibility of bioinks, can payload stem cells, meet the 3D printing needs of tissue repair, and provide long-term repair results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015499A_ABST
    Figure CN119015499A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedical polymer materials, and discloses novel bio-ink and application thereof in treatment of glottis insufficiency, the bio-ink comprises the following components by weight: 3-5% of GeIMA, 2-4% of AAM, 1-5% of PEGDA, 1-3% of PEO and 7-9% of Gelatin. The novel bio-ink provided by the invention is excellent in performance, good in compression resistance, good in biocompatibility and good in printability, and can meet 3D printing of stem cell loaded grade porous hydrogel scaffolds required by tissue repair.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomedical polymer materials, and more specifically, to a novel bio-ink and its application in treating glottic insufficiency. Background Art

[0002] Glottic insufficiency has a high incidence in clinical practice. The main treatment strategy is to use injection or open surgery to promote the inward movement of the vocal cords and improve the voice quality by narrowing the glottic fissure. However, existing injection materials still face problems such as easy absorption, poor long-term efficacy, and repeated injections. Therefore, the construction of implantable 3D hierarchical pore scaffold structures is crucial. 3D printing technology has become the most promising method for repairing 3D scaffold structures because it can quickly, accurately, and personalized customize individual needs in different situations. Hierarchical pore hydrogels have a microenvironment close to the natural extracellular matrix, and the injectability of hierarchical pore hydrogels gives them minimally invasive characteristics, which is a very promising development direction for repair treatment. In addition to the pore structure, mechanical properties, biocompatibility, injectability, and degradability of the hydrogel, the design of bioprinting inks must also consider printability and the uniformity and stability of the bioink. Traditional bioinks are often selected as single components. In recent years, the development trend of bioinks is a combination of two or more materials.

[0003] The most promising method for preparing injectable porous hydrogel scaffold bio-ink is the liquid phase template method. The liquid phase template method is based on the "two-phase aqueous" system, which is formed by phase separation of two incompatible polymer dispersions exceeding the critical concentration29). The "two-phase aqueous" bio-ink is obtained by mixing the GelMA hydrogel precursor and the liquid phase template PEO. After 3D printing, the GeIMA phase is photo-crosslinked and fixed, and the uncrosslinked PEO phase can be removed to form a porous hydrogel scaffold structure. The liquid phase template method can obtain a connected pore structure with a pore size of more than 50 microns, achieving a breakthrough in the design of hydrogel pore structure. However, the presence of the pore structure also reduces the mechanical properties of the GelMA hydrogel, making it difficult to directly apply it to tissue repair. Therefore, it is necessary to improve the mechanical properties of the hydrogel to match the mechanical properties of the tissue. Although the concentration of the hydrogel can be increased by increasing the concentration of the GelMA cross-linking phase, in order to maintain the stability of the bio-ink, the concentration of the pore-forming phase must be increased at the same time, making it difficult to form a pore structure. The development of bio-ink has encountered a bottleneck. For a long time, there have been few reports on the use of injectable 3D printed hierarchical pore hydrogel scaffolds for repairing tissue defects. They can only be shaped by traditional casting methods or injected into the human body and then cross-linked and shaped.

[0004] Therefore, the present invention proposes a new type of biological ink to solve the above technical problems. Summary of the invention

[0005] In order to overcome the above-mentioned defects in the prior art, the present invention provides a new type of bio-ink and its application in the treatment of glottic incomplete closure. The new type of bio-ink proposed in the present invention has excellent performance, good compression resistance, good biocompatibility, and good printability, and can meet the 3D printing of stem cell-loaded hierarchical hydrogel scaffolds required for tissue repair.

[0006] The above technical objectives of the present invention are achieved through the following technical solutions: A new type of biological ink and its application in treating glottic insufficiency, comprising the following components in weight percentage:

[0007] 3-5% GeIMA, 2-4% AAM, 1-5% PEGDA, 1-3% PEO and 7-9% Gelatin;

[0008] Application of a new type of bio-ink in the treatment of glottic insufficiency.

[0009] In summary, the present invention has the following beneficial effects: the new bio-ink proposed in the present invention has excellent performance, good compression resistance, good biocompatibility, good printability, and can meet the 3D printing of stem cell-loaded hierarchical hydrogel scaffolds required for tissue repair. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 A is a bright field image of the bio-ink under a microscope in an embodiment of the present invention;

[0011] Figure 1 B is a picture of the bio-ink in an embodiment of the present invention under microscope fluorescence;

[0012] Figure 2 It is a diagram showing the phenomenon of emulsion stratification of the pore-forming phase and the biological ink in the embodiment of the present invention and the phenomenon of emulsion cross-linking of 10% GeIMA and GPA;

[0013] Figure 3 A is a pore size diagram of the bio-ink under a fluorescence microscope when the concentration of Gelatin in the embodiment of the present invention is 7%, 8%, 9% and the mixing time is 6S, 8S, 10S, and 12S;

[0014] Figure 3 B is the average pore size and frequency distribution diagram of the bio-ink when the concentration of Gelatin is 7%, 8%, 9% and the mixing time is 6S, 8S, 10S, and 12S in the embodiment of the present invention;

[0015] Figure 4 A is the morphology and microstructure of the bio-ink before (relaxed), during (compressed), and after (relaxed) compression testing in an embodiment of the present invention;

[0016] Figure 4 B is a graph showing the changes in the diameter and average pore size of the bio-ink in an embodiment of the present invention with 50 compression test cycles;

[0017] Figure 5 A is a graph showing the rheological test results of three bio-inks, GPA, GA and 10% GeIMA, in an embodiment of the present invention;

[0018] Figure 5 B is a graph showing the mechanical test results of three bio-inks, GPA, GA and 10% GeIMA, in an embodiment of the present invention;

[0019] Figure 6 A is a diagram showing the injectability of the bio-ink in an embodiment of the present invention;

[0020] Figure 6 B is a pattern of 3D printing of biological ink in an embodiment of the present invention;

[0021] Figure 7 A is a live-dead staining image of the bio-ink in an embodiment of the present invention;

[0022] Figure 7 B is a live-death ratio diagram of cells at 1d, 4d, and 7d in an embodiment of the present invention;

[0023] Figure 7 C is a graph showing the experimental results of CCK-8 on cells at 1d, 4d, and 7d in an embodiment of the present invention;

[0024] Figure 7 D is a cell migration experiment and cell density diagram of cells in an embodiment of the present invention;

[0025] Figure 8 A is the bright field and red fluorescence field observation diagram of the degradation performance of the hydrogels in the embodiments of the present invention, G hydrogel, GA hydrogel and GPA hydrogel at different time points;

[0026] Figure 8 B, C, and D are the quantitative analysis diagrams of in vitro degradation of G hydrogel, GA hydrogel, and GPA hydrogel, respectively; DETAILED DESCRIPTION

[0027] The following is combined with Figure 1-8 The present invention is described in further detail.

[0028] Example: To investigate the in vitro degradation properties of G hydrogel, GA hydrogel, and GPA hydrogel: At 37°C, immerse in PBS solution for 24 hours to reach a swelling equilibrium state, and then weigh them one by one, and record the initial mass of the material sample as Wd. Each group of samples was then placed in a 0.0001% type I collagenase DMEM solution. This step was used to simulate the concentration of type I collagenase in the paraglottic space environment. The samples were gently shaken at 37°C, with the preset time points being 0h, 1d, 3d, 5d, and 7d. The remaining mass (Ws) of the material sample was recorded in order at each preset point. Finally, the data was sorted to calculate the degradation kinetics, and the material degradation rate calculation formula is as follows:

[0029] Degradation rate = (Wd-Ws) / Ws×100%

[0030] The above experiment was repeated 3 times, and the data results were imported into Origin to analyze the degradation rate, observe the degradation characteristics of hydrogels with different components, and obtain the optimal configuration of porous hydrogel with target pore size. The results of the degradation experiment are shown in Figure 8 shown.

[0031] By modifying biomaterials to adjust material degradation to match in situ tissue regeneration. Figure 8 It can be seen that G hydrogel, GA hydrogel and GPA hydrogel were completely degraded in 10h, 54h and 10d respectively. G hydrogel degraded 50% of the hydrogel in 5h and degraded at a constant rate after 5h; GA hydrogel degraded 50% of the hydrogel in 9h, and then degraded slowly after 9h; GPA hydrogel degraded 50% of the hydrogel in 5d, and degraded at a constant rate after 5d, as shown in the figure. This shows that after the addition of PEGDA, the degradation rate is effectively slowed down. In summary, with the addition of enzymes, G hydrogel has been completely degraded in 10h, but previous studies have shown that G hydrogel is completely degraded in animals in about 2w, but this cannot meet the requirements of this study for filling materials. This study hopes that the hydrogel used to repair incomplete glottal closure has a long-term repair effect. After adding AM, the degradation rate of the hydrogel slowed down, but it still could not meet the requirements of this study for the hydrogel; after adding AM and PEGDA, the hydrogel was completely degraded in 10 days, which was 24 times the degradation rate of the G hydrogel, which met the requirement that the hydrogel had a long-term filling effect.

[0032] like Figure 1 A and Figure 1 B shows the bright field image of the bio-ink under a microscope and the fluorescence image of the bio-ink under a microscope.

[0033] like Figure 2As shown in the figure, the pore-forming phase and the bio-ink solution were placed at 26°C for 30 minutes to undergo emulsion stratification; 10% GeIMA and GPA were placed at 20°C for 5 minutes to undergo emulsion cross-linking. It can be concluded that bio-ink has different properties at different temperatures. The stability of bio-ink was further explored at different temperatures.

[0034] Pore ​​size study of bio-ink: When the concentration of Gelatin in the PEO phase is set to 7%, 8% and 9%, and when it is mixed with the GeIMA phase for 8S, we can find that there is a significant difference in the pore size of the hydrogel. When we mix the PEO phase with the GeIMA phase for 6S, 8S, 10S and 12S, there is also a significant difference in the pore size of the hydrogel. Figure 3 As shown in A, it is the pore size diagram of the bio-ink under a fluorescence microscope when the concentration of Gelatin is 7%, 8%, 9% and the mixing time is 6S, 8S, 10S, and 12S. The average pore size and frequency distribution are converted into a bar graph as shown in Figure 3 As shown in B, it can be seen that the average pore size and frequency distribution of the bio-ink are when the concentration of Gelatin is 7%, 8%, 9% and the mixing time is 6S, 8S, 10S, and 12S.

[0035] Study on the physical properties of bio-ink:

[0036] The bio-ink was repeatedly squeezed (doubling its diameter) to observe the morphology and microstructure of the bio-ink before (relaxation), during (compression), and after (relaxation) the compression test, as well as the changes in the diameter and average pore size of the bio-ink over 50 compression test cycles, e.g. Figure 4 A and Figure 4 As shown in B, it was found that it was not damaged.

[0037] The GPA hydrogel exhibits superior rheological and mechanical properties to the 10% GeIMA hydrogel, mainly in terms of G', G", Young's modulus and compressibility. Figure 5 A and Figure 5 As shown in B, the rheological test results of three bio-inks, GPA, GA and 10% GeIMA, and the mechanical test results of three hydrogels, GPA, GA and 10% GeIMA.

[0038] The 3D printing of bio-ink and its injectability are shown in Table 1

[0039]

[0040] In order to further explore the injectability of GPA hydrogel, we used syringes of different sizes to test the injectability of GPA hydrogel. We found that GPA hydrogel can still pass smoothly when using a 20G syringe, which shows that the injectability of GPA hydrogel is very good. Figure 6 As shown in A.

[0041] Biocompatibility of bio-ink:

[0042] The GPA hydrogel extract was subjected to live-dead staining. The staining results after 1, 4, and 7 days were as follows: Figure 7 As shown in A, its life and death Figure 7 As shown in B, its life and death Figure 7 As shown in B, the live-death ratio of cells is as high as over 90%, which indicates that the biocompatibility of GPA hydrogel is very good. CCK-8 and cell migration experiments were performed on it at the same time. The experimental results of CCK-8 on cells at 1d, 4d, and 7d are shown in Figure 7 C. Cell migration assay and cell density Figure 7 As shown in D, it is concluded that the new GPA hydrogel provided by the present invention has excellent biocompatibility.

[0043] In summary, it is concluded that the new bio-ink proposed in the present invention has excellent performance, good compression resistance, good biocompatibility, good printability, and can meet the needs of 3D printing of stem cell-loaded hierarchical hydrogel scaffolds for tissue repair.

[0044] This specific embodiment is merely an explanation of the present invention and is not a limitation of the present invention. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed. However, as long as they are within the scope of the claims of the present invention, they are protected by the patent law.

Claims

1. A novel bio-ink, characterized in that: The composition comprises the following components in weight percentage: 3-5% GeIMA, 2-4% AAM, 1-5% PEGDA, 1-3% PEO and 7-9% Gelatin.

2. Application of a novel bio-ink according to claim 1 in the treatment of glottic insufficiency.